Related Experiment Video

Updated: Sep 1, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment

Tong Zhang1,2, Haixiang Yu3, Xiangpeng Dai1,2

  • 1Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, China.

Frontiers in Immunology
|August 12, 2022
PubMed

Insights

Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing 6 (CMTM6) and CMTM4 proteins regulate the tumor microenvironment (TME) by modulating PD-L1. These proteins offer potential as biomarkers and immunotherapy targets for cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The tumor microenvironment (TME) is critical in cancer progression, metastasis, and drug resistance.
  • Understanding TME regulation is key to advancing tumor biology insights.
  • The roles of specific proteins in TME modulation remain largely elusive.

Purpose of the Study:

  • To review the function of CMTM6 and CMTM4 in modulating TME components.
  • To explore the involvement of CMTM6 and CMTM4 in PD-L1 post-translational regulation.
  • To highlight clinical applications and future research directions for CMTM6/4.

Main Methods:

  • Literature review and synthesis of existing research on CMTM6 and CMTM4.
  • Analysis of the impact of CMTM6 and CMTM4 on immune and tumor cells within the TME.
  • Discussion of PD-L1 regulation by CMTM6 and CMTM4.

Main Results:

  • CMTM6 and CMTM4 play significant roles in regulating TME composition and function.
  • These proteins are involved in the post-translational modification of PD-L1, influencing immune responses.
  • Their functions impact immune cell and tumor cell behavior within the TME.

Conclusions:

  • CMTM6 and CMTM4 are key regulators of the tumor microenvironment and PD-L1 expression.
  • These proteins represent promising biomarkers for predicting therapy efficacy.
  • CMTM6 and CMTM4 are potential targets for novel immunotherapies and combination treatments.
Keywords:
CMTM4CMTM6CTLM2 macrophageMDSCPD-L1TMETreg

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

999
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K